NewAmsterdam Pharma Company N.V. Warrant - NAMSW STOCK NEWS

NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee approved inducement share options for three new non-executive employees. A total of 195,000 ordinary shares were granted under the 2024 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $20.58 per share, matching the closing price on July 1, 2024. The shares will vest over four years, starting with 25% on the one-year anniversary of the vesting commencement date, followed by 36 equal monthly installments, subject to continued employment.

NewAmsterdam Pharma announced that the United States Patent and Trademark Office (USPTO) has issued a new composition of matter patent for obicetrapib, extending its patent protection until July 2043. This patent covers amorphous obicetrapib hemicalcium, the solid form to be used in the company's products, and will be listed in the FDA's Orange Book if approved. The USPTO has issued or allowed nine patents for obicetrapib and its applications. CEO Michael Davidson highlighted that this new patent extends protection more than 9 years beyond the previous patent, facilitating ongoing Phase 3 trials and long-term benefits from obicetrapib's innovation.

NewAmsterdam Pharma (Nasdaq: NAMS), a biopharmaceutical company developing oral, non-statin medicines for cardiovascular disease (CVD) patients with elevated LDL-C, announced the approval of inducement share options for five new non-executive hires. The Compensation Committee granted options for a total of 90,000 ordinary shares under the 2024 Inducement Plan. These options, priced at $18.92 per share based on the June 3, 2024 market close, will vest over four years: 25% after one year and the remaining 75% in equal monthly installments over the next three years, contingent upon continued employment. The grants adhere to Nasdaq Listing Rule 5635(c)(4).

NewAmsterdam Pharma, a late-stage clinical biopharmaceutical company developing non-statin medicines for cardiovascular disease patients with elevated LDL-C, announced its management's participation in two upcoming investor conferences.

On June 5, 2024, the company will attend the Jefferies Global Healthcare Conference in New York, where CEO Michael Davidson and CFO Ian Somaiya will engage in a fireside chat at 3:00 p.m. ET.

On June 10, 2024, CEO Michael Davidson will present a corporate overview at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach at 10:40 a.m. ET. Live webcasts of both events will be available on the company's investor relations website, with replays accessible post-event.

NewAmsterdam Pharma (Nasdaq: NAMS) announced it will present new clinical and preclinical data on obicetrapib, a novel oral therapy for hypercholesterolemia, at two major upcoming medical meetings. The data, derived from the OCEAN, ROSE, and ROSE2 Phase 2 trials, show obicetrapib's impact on key lipid and lipoprotein biomarkers. The presentations will occur at the European Atherosclerosis Society (EAS) 92nd Congress in Lyon, France, and the National Lipid Association (NLA) 2024 Scientific Sessions in Las Vegas, Nevada. The company is also on track to report topline data from its Phase 3 BROOKLYN trial in HeFH by Q3 2024 and its Phase 3 BROADWAY trial in ASCVD by Q4 2024.

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) provides corporate updates and financial results for the first quarter of 2024. The company enrolled over 9,500 patients in Phase 3 trials, reported strong financial position with $481.1 million in cash, and is on track to report topline data from upcoming trials. NewAmsterdam continues to develop obicetrapib, focusing on improving LDL-C goals for patients at risk of cardiovascular disease.

NewAmsterdam Pharma Company N.V. announced the grant of inducement share options to three non-executive new hires under the 2024 Inducement Plan. The options cover 30,000 ordinary shares, with an exercise price of $21.97 per share. The shares will vest over four years, with 25% vesting after one year and the rest in monthly installments, contingent on continued service.

NewAmsterdam Pharma Company N.V. will host an R&D Day event on May 16, 2024, to discuss obicetrapib's clinical development path and NewAmsterdam's commercial strategy with key opinion leaders in cardiovascular disease. The event will feature renowned specialists and will be live webcasted.

NewAmsterdam Pharma Company N.V. (NAMS) has successfully achieved its enrollment target of 9,000 patients for the Phase 3 PREVAIL cardiovascular outcomes trial evaluating obicetrapib, a potential treatment for patients with cardiovascular disease. The company plans to extend enrollment to accommodate strong interest, with expectations to randomize over 9,000 patients by the end of April. Driven by the need for more effective therapies for patients with elevated LDL-C levels, NewAmsterdam aims to demonstrate obicetrapib's potential to reduce major adverse cardiac events and improve outcomes for those at risk of serious cardiovascular conditions.